For this reason, PARP7 inhibition could represent a valid anticancer strategy based on immunomodulatory effects through IFN-I response restoration that can allow the immune recognition of cancer cells and reverse immunoevasion [61]. The gene discussed is TIPARP; the disease is cancer.